Form 4: Evoke Pharma Director Greg Pyszczymuka Acquires Stock Options
SEC Filing
Director Greg Pyszczymuka of Evoke Pharma Inc. reports the acquisition of stock options.
Summary
- Greg Pyszczymuka, a director of Evoke Pharma Inc., filed a Form 4 indicating a transaction involving derivative securities.
- On February 20, 2025, Pyszczymuka acquired stock options for 5,833 shares of common stock at an exercise price of $5.26.
- These options vest in three equal installments annually, starting February 20, 2025, contingent upon continued service to Evoke Pharma.
- Following the transaction, Pyszczymuka directly owns 5,833 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the compensation and equity ownership of company directors.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment as it aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/20/2025 | Date of earliest transaction: Grant date of stock options. |
| 02/20/2025 | First vesting date of the stock options. |
| 02/19/2035 | Expiration date of the stock options. |
| 02/24/2025 | Date of Form 4 filing. |
Keywords
Form 4, Evoke Pharma, Stock Options, Director, Pyszczymuka, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.